Business Context and Reporting Period
This Form 8-K, filed on January 11, 2026, by IDEAYA Biosciences, Inc. (IDYA), details a business update and corporate objectives for 2026. The company is a biopharmaceutical firm focused on developing targeted therapies, with a primary emphasis on uveal melanoma and neuroendocrine cancers. The update was provided in anticipation of a presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
Key Financial Metrics
The filing provides limited financial data, focusing primarily on liquidity to support the operating plan.
- Liquidity: As of September 30, 2025, the company held approximately $1.1 billion in cash, cash equivalents, and marketable securities.
- Runway: Management expects current liquidity to fund the operating plan into 2030.
- Revenue, Profit, and Debt: The filing text does not provide specific values for revenue, net income, operating margins, or debt levels.
Material Changes and Clinical Progress
The report outlines significant milestones in the company's clinical pipeline, marking a transition toward registrational trials and potential approvals.
- Darovasertib (Uveal Melanoma):
- Topline progression-free survival (PFS) data from the Phase 2/3 OptimUM-02 trial (first-line HLA*A2-negative metastatic UM) is expected in Q1 2026.
- Full enrollment of 437 patients in OptimUM-02 was completed as of December 2025.
- The company anticipates initiating three randomized Phase 3 registrational trials across all stages of uveal melanoma by H1 2026.
- Enrollment of approximately 80 HLA*A2-positive patients in the single-arm OptimUM-01 trial is expected by Q2 2026.
- Antibody-Drug Conjugates (ADCs):
- IDE849: Target to initiate a monotherapy registrational study in second-line/refractory small cell lung cancer (SCLC) and/or neuroendocrine carcinomas by the end of 2026.
- IDE034: Phase 1 dose escalation trial initiation expected in Q1 2026.
- IDE161: Clinical combination studies with IDE849 planned for Q2 2026.
- MTAP Pathway:
- IDE397: Updated Phase 1/2 combination data with Trodelvy in MTAP-deleted urothelial cancer expected at a 2026 medical conference.
- IDE892: Phase 1 monotherapy trial initiation expected in Q1 2026.
- CDKN2A Program: IND application submission targeted for the end of 2026.
- Next Generation Therapies:
- IDE574: Phase 1 dose escalation trial initiation expected in Q1 2026.
Guidance, Outlook, and Risks
Management's outlook is centered on advancing four registrational trials and achieving commercial readiness for darovasertib in partnership with Les Laboratoires Servier. Key forward-looking statements include the potential for an accelerated approval filing for darovasertib in the U.S. if Q1 2026 PFS data is positive, and the use of overall survival data to support a full approval filing.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ due to uncertainties regarding clinical trial outcomes, regulatory approvals, patient enrollment timelines, and the sufficiency of cash resources to fund operations through 2030.
Investor Verification Checklist
- Verify the Q1 2026 topline PFS results from the OptimUM-02 trial for darovasertib.
- Confirm the timeline for the potential accelerated approval filing for darovasertib in the U.S.
- Monitor the initiation dates for the three planned Phase 3 registrational trials for darovasertib.
- Track the start of the IDE849 registrational study in SCLC/NEC by the end of 2026.
- Review the company's cash burn rate to ensure the $1.1 billion liquidity position remains sufficient to fund operations into 2030.